Mari F.C.M. van den Hout

Prognosis in Patients With Sentinel Node–Positive Melanoma Is Accurately Defined by the Combined Rotterdam Tumor Load and Dewar Topography Criteria

Augustinus P. T. van der Ploeg, Alexander C. J. van Akkooi, Piotr Rutkowski et al. · Journal of Clinical Oncology · 2011 · 207 citations · Full text

Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC)

Emma J. de Ruiter, Frans J. Mulder, Bregje M Koomen et al. · Modern Pathology · 2020 · 138 citations · Full text

Tumor Biology, Pd-l1 Immunohistochemical Assays, Cancer Immunosurveillance +9

Characterization of four conventional dendritic cell subsets in human skin-draining lymph nodes in relation to T-cell activation

Rieneke van de Ven, Mari F.C.M. van den Hout, Jelle J. Lindenberg et al. · Blood · 2011 · 91 citations · Full text

Local Adjuvant Treatment with Low-Dose CpG-B Offers Durable Protection against Disease Recurrence in Clinical Stage I–II Melanoma: Data from Two Randomized Phase II Trials

Bas D. Koster, Mari F.C.M. van den Hout, Berbel J.R. Sluijter et al. · Clinical Cancer Research · 2017 · 62 citations · Full text

Arming the Melanoma Sentinel Lymph Node through Local Administration of CpG-B and GM-CSF: Recruitment and Activation of BDCA3/CD141+ Dendritic Cells and Enhanced Cross-Presentation

Berbel J.R. Sluijter, Mari F.C.M. van den Hout, Bas D. Koster et al. · Cancer Immunology Research · 2015 · 61 citations